share_log

Investors Should Be Encouraged By APT Medical's (SHSE:688617) Returns On Capital

Investors Should Be Encouraged By APT Medical's (SHSE:688617) Returns On Capital

APT Medical(上海證券交易所代碼:688617)的資本回報率應鼓勵投資者
Simply Wall St ·  03/19 18:32

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. And in light of that, the trends we're seeing at APT Medical's (SHSE:688617) look very promising so lets take a look.

如果我們想找到一隻可以長期成倍增長的股票,我們應該尋找哪些潛在趨勢?在一個完美的世界中,我們希望看到一家公司向其業務投入更多資本,理想情況下,從這些資本中獲得的回報也在增加。如果你看到這一點,這通常意味着它是一家擁有良好商業模式和大量盈利再投資機會的公司。有鑑於此,我們在APT Medical's(上海證券交易所代碼:688617)看到的趨勢看起來非常有希望,所以讓我們來看看吧。

Return On Capital Employed (ROCE): What Is It?

資本使用回報率(ROCE):這是什麼?

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for APT Medical, this is the formula:

如果你以前沒有與ROCE合作過,它會衡量公司從其業務中使用的資本中產生的 “回報”(稅前利潤)。要計算 APT Medical 的這個指標,公式如下:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)

0.33 = CN¥608m ÷ (CN¥2.4b - CN¥574m) (Based on the trailing twelve months to December 2023).

0.33 = 6.08億元人民幣 ÷(24億元人民幣-5.74億元人民幣) (基於截至2023年12月的過去十二個月)

So, APT Medical has an ROCE of 33%. That's a fantastic return and not only that, it outpaces the average of 9.2% earned by companies in a similar industry.

因此,APT Medical的投資回報率爲33%。這是一個了不起的回報,不僅如此,它還超過了類似行業公司9.2%的平均收入。

roce
SHSE:688617 Return on Capital Employed March 19th 2024
SHSE: 688617 2024 年 3 月 19 日動用資本回報率

In the above chart we have measured APT Medical's prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for APT Medical .

在上圖中,我們將APT Medical先前的投資回報率與之前的表現進行了比較,但可以說,未來更爲重要。如果您有興趣,可以在我們的APT Medical免費分析師報告中查看分析師的預測。

What Can We Tell From APT Medical's ROCE Trend?

我們可以從APT Medical的投資回報率趨勢中得出什麼?

Investors would be pleased with what's happening at APT Medical. The data shows that returns on capital have increased substantially over the last five years to 33%. The amount of capital employed has increased too, by 612%. So we're very much inspired by what we're seeing at APT Medical thanks to its ability to profitably reinvest capital.

投資者會對APT Medical發生的事情感到滿意。數據顯示,在過去五年中,資本回報率大幅上升至33%。使用的資本金額也增加了612%。因此,我們在APT Medical所看到的情況給我們帶來了極大的啓發,這要歸功於它能夠盈利地進行資本再投資。

The Bottom Line

底線

A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what APT Medical has. And with the stock having performed exceptionally well over the last three years, these patterns are being accounted for by investors. In light of that, we think it's worth looking further into this stock because if APT Medical can keep these trends up, it could have a bright future ahead.

一家資本回報率不斷提高且能夠持續進行自我再投資的公司是一個備受追捧的特徵,而這正是APT Medical所擁有的。而且,由於該股在過去三年中表現異常出色,投資者正在考慮這些模式。有鑑於此,我們認爲值得進一步研究這隻股票,因爲如果APT Medical能夠保持這些趨勢,它可能會有一個光明的未來。

On the other side of ROCE, we have to consider valuation. That's why we have a FREE intrinsic value estimation for 688617 on our platform that is definitely worth checking out.

在ROCE的另一方面,我們必須考慮估值。這就是爲什麼我們在平台上免費提供688617的內在價值估算值的原因,絕對值得一試。

If you want to search for more stocks that have been earning high returns, check out this free list of stocks with solid balance sheets that are also earning high returns on equity.

如果你想搜索更多獲得高回報的股票,可以查看這份資產負債表穩健且淨資產回報率也很高的股票的免費清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論